Though anselamimab failed its Phase 3 test in light chain amyloidosis, AstraZeneca points to encouraging results in a pre-defined patient subgroup — which may not be a winning strategy. Prothena resurrected its failed drug candidate for the disease based on a subgroup analysis, only to see that antibody fall short in a pivotal study.
The post AstraZeneca Blockbuster Prospect Is a Bust in Pivotal Test in Light Chain Amyloidosis appeared first on MedCity News.
